Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m(2)), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation base...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Cancer J
Hoofdauteurs: Dhakal, Binod, D’Souza, Anita, Hamadani, Mehdi, Arce-Lara, Carlos, Schroeder, Katrina, Chhabra, Saurabh, Shah, Nirav N., Gauger, Katelyn, Keaton, Taylor, Pasquini, Marcelo, Hari, Parameswaran
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6663939/
https://ncbi.nlm.nih.gov/pubmed/31358733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0219-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items